Diligence memo · auto-generated · as of July 2, 2026
ByHeart, Inc.
ByHeart, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
ByHeart, Inc. operates in Other Health Care, based in New York. ByHeart is an infant formula company committed to quality, safety, and transparency. Learn more about our mission and path forward.
Capital & rounds (filed)filed
ByHeart, Inc. has raised $378M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $97M on 2020-03-18.
Most recent recorded round closed around 2025-03-12.
Valuation (modeled)modeled
Provath models ByHeart, Inc. at approximately $494M (range $262M–$682M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.18× the median modeled value of Series C Other Health Care companies in 2025–2027 (20 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 9 months.
Last raise 16 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 99% of Other Health Care peers (5377 compared).
Modeled value ranks above 93% of those peers.
Closest niche peers: RESTOR3D, Inc., SpyGlassPharma, Inc., VantAI Holdings, Inc., BioIntelliSense, Inc., ObjectiveHealth, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.